Newstral
Article
jdsupra.com on 2018-01-31 00:53
In re Janssen Biotech, Inc. (Fed. Cir. 2018)
Related news
- USPTO Files Response Brief in In re Janssen Biotech, Inc. & New York Universityjdsupra.com
- In Re: Janssen Biotech, Inc.jdsupra.com
- Braintree Laboratories, Inc. v. Breckenridge Pharmaceutical, Inc. (Fed. Cir. 2017)jdsupra.com
- Merck Sharp & Dohme Corp. v. Hospira, Inc. (Fed. Cir. 2017)jdsupra.com
- In re BigCommerce, Inc. (Fed. Cir. 2018)jdsupra.com
- In re NuVasive, Inc. (Fed. Cir. 2016)jdsupra.com
- In re Depomed, Inc. (Fed. Cir. 2017)jdsupra.com
- In re Cray Inc. (Fed. Cir. 2017)jdsupra.com
- Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2024)jdsupra.com
- In re ZTE (USA) Inc. (Fed. Cir. 2018)jdsupra.com
- In re Qapsule Technologies, Inc. (Fed. Cir. 2019)jdsupra.com
- Amgen Inc. v. Sanofi (Fed. Cir. 2021)jdsupra.com
- Nantkwest, Inc. v. Matal (Fed. Cir. 2017)jdsupra.com
- Amgen Inc. v. Sanofi (Fed. Cir. 2017)jdsupra.com
- Barry v. Medtronic, Inc. (Fed. Cir. 2019)jdsupra.com
- Genentech, Inc. v. Iancu (Fed. Cir. 2020)jdsupra.com
- Amgen Inc. v. Vidal (Fed. Cir. 2022)jdsupra.com
- TriVascular, Inc. v. Samuels (Fed. Cir. 2016)jdsupra.com
- Pfizer, Inc. v. Lee (Fed. Cir. 2016)jdsupra.com
- Berkheimer v. HP Inc. (Fed. Cir. 2018)jdsupra.com